Cellectar Biosciences
CLRB
20 hedge funds and large institutions have $2.14M invested in Cellectar Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 13 closing their positions.
0.31% more ownership
Funds ownership: 0.04% → 0.35% (+0.31%)
35% less funds holding
Funds holding: 31 → 20 (-11)
41% less capital invested
Capital invested by funds: $3.65M → $2.14M (-$1.51M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$71.9K |
| 2 |
1WM
1900 Wealth Management
San Antonio,
Texas
|
+$57.5K |
| 3 |
DCM
Difesa Capital Management
New York
|
+$43.1K |
| 4 |
Renaissance Technologies
New York
|
+$5.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$71.9K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$44.4K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$39K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28K |
| 5 |
CAM
Cozad Asset Management
Champaign,
Illinois
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CB
26
Commerce Bank
Kansas City,
Missouri
| – | -$6K | -48 | Closed |
|
27
Jane Street
New York
| – | -$5K | -45 | Closed |
|
|
SC
28
Scotia Capital
Toronto,
Ontario, Canada
| – | -$5K | -38 | Closed |
|
|
JFGIW
29
Johnson Financial Group Inc (Wisconsin)
Racine,
Wisconsin
| – | -$2K | -18 | Closed |
|
|
PFS
30
Prospera Financial Services
Dallas,
Texas
| – | -$2K | -18 | Closed |
|
31
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -7 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$1K | -5 | Closed |
|
CLRB Hedge Fund Activity: Q3 2022 in Review
20 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2022, worth a combined $2.14M — down 41% from $3.65M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLRB and 2 opened new positions — a net loss of 11 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $71.9K. The largest seller was Maven Securities, cutting an estimated $71.9K.
- 20 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2022, down from 31 in Q2 2022.
- Funds reported $2.14M of Cellectar Biosciences stock for Q3 2022, down 41% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q3 2022 and 13 closed out, a net change of -11 holders.
- The largest Cellectar Biosciences buyer in Q3 2022 was Morgan Stanley, an estimated $71.9K added.
- The largest Cellectar Biosciences seller in Q3 2022 was Maven Securities, an estimated $71.9K sold.
Based on aggregated 13F filings for Q3 2022.